Substituted Pyridine PARP1 Inhibitors for Reduced PARP2 Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet medical need for PARP inhibitors with improved selectivity for PARP1 to enhance efficacy and reduce toxicity, particularly in treating cancers with homologous recombination deficiency (HRD) and BRCA1/2 mutations.
Innovation Solution
Development of compounds of Formula (I) or their pharmaceutically acceptable salts, solvates, or stereoisomers, which selectively inhibit PARP1, potentially trapping it on DNA to induce DNA double strand breaks, thereby selectively killing tumor cells with HRD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PARP inhibitors are used to treat cancers with HRD and BRCA1/2 mutations, then efficacy is improved, but toxicity increases
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features (substituted pyridine core with particular R1-R8 groups) that confer selective binding to PARP1 over PARP2. This selectivity localizes the inhibitory effect primarily to PARP1, improving therapeutic index by reducing off-target toxicity while maintaining efficacy against HRD/BRCA-mutant cancers.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters (substituents R1-R8, ring structures A and B) to optimize the balance between potency and selectivity. By adjusting these molecular parameters, the invention achieves inhibitors that maintain strong activity against PARP1 in cancer cells while reducing inhibition of PARP2 in normal cells, thereby improving the efficacy-toxicity ratio.
2Reliability
If selectivity for PARP1 is increased to reduce toxicity, then therapeutic index is improved, but inhibitor design complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional modules: a core pyridine structure (providing PARP1 selectivity) and variable substituent groups R1-R8 (tuning potency and pharmacokinetic properties). This modular segmentation allows independent optimization of selectivity and activity, simplifying the design process while achieving high selectivity.
Solution Approach 2:
The patent uses parameter changes by defining specific ranges and options for each substituent (R1-R8) and ring structure (A and B) that systematically explore the chemical space for optimal selectivity. This parameterized approach provides a structured methodology for designing selective inhibitors without requiring de novo optimization of each molecular feature.
Data Source
AI summary
Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.